Does the media refer more to CORT or ANVS?

In the previous week, Corcept Therapeutics had 13 more articles in the media than Annovis Bio. MarketBeat recorded 14 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.39 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZTS or CORT?

In the previous week, Zoetis had 30 more articles in the media than Corcept Therapeutics. MarketBeat recorded 44 mentions for Zoetis and 14 mentions for Corcept Therapeutics. Zoetis' average media sentiment score of 0.69 beat Corcept Therapeutics' score of 0.39 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 20 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Corcept Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RPRX or CORT?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Royalty Pharma. MarketBeat recorded 14 mentions for Corcept Therapeutics and 3 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.52 beat Corcept Therapeutics' score of 0.39 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corcept Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer JAZZ or CORT?

In the previous week, Jazz Pharmaceuticals had 1 more articles in the media than Corcept Therapeutics. MarketBeat recorded 15 mentions for Jazz Pharmaceuticals and 14 mentions for Corcept Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.48 beat Corcept Therapeutics' score of 0.39 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 8 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Corcept Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CORT or SUPN?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 14 mentions for Corcept Therapeutics and 3 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.39 beat Supernus Pharmaceuticals' score of 0.28 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Corcept Therapeutics (CORT) Competitors

$79.85 +0.14 (+0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$81.28 +1.44 (+1.80%)

As of 07:58 PM Eastern

Compare

CORT vs. ANVS, ZTS, RPRX, JAZZ, and SUPN

Should you buy Corcept Therapeutics stock or one of its competitors? MarketBeat compares Corcept Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corcept Therapeutics include Annovis Bio (ANVS), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "medical" sector.

How does Corcept Therapeutics compare to Annovis Bio?

Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Corcept Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Corcept Therapeutics has a net margin of 6.14% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 7.40% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Annovis Bio	N/A	-318.08%	-215.47%

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Corcept Therapeutics had 13 more articles in the media than Annovis Bio. MarketBeat recorded 14 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.39 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	11.26	$99.65M	$0.35	228.14
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Corcept Therapeutics presently has a consensus price target of $88.83, suggesting a potential upside of 11.25%. Annovis Bio has a consensus price target of $13.50, suggesting a potential upside of 682.61%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Corcept Therapeutics beats Annovis Bio on 13 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Zoetis?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zoetis has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Zoetis presently has a consensus price target of $133.92, suggesting a potential upside of 74.26%. Corcept Therapeutics has a consensus price target of $88.83, suggesting a potential upside of 11.25%. Given Zoetis' higher probable upside, equities analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.14%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Corcept Therapeutics	6.14%	7.40%	5.76%

In the previous week, Zoetis had 30 more articles in the media than Corcept Therapeutics. MarketBeat recorded 44 mentions for Zoetis and 14 mentions for Corcept Therapeutics. Zoetis' average media sentiment score of 0.69 beat Corcept Therapeutics' score of 0.39 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	20 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Corcept Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.40	$2.67B	$6.03	12.74
Corcept Therapeutics	$761.41M	11.26	$99.65M	$0.35	228.14

Summary

Zoetis beats Corcept Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Royalty Pharma presently has a consensus price target of $53.71, suggesting a potential downside of 2.96%. Corcept Therapeutics has a consensus price target of $88.83, suggesting a potential upside of 11.25%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Corcept Therapeutics had 11 more articles in the media than Royalty Pharma. MarketBeat recorded 14 mentions for Corcept Therapeutics and 3 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.52 beat Corcept Therapeutics' score of 0.39 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Corcept Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has a net margin of 33.88% compared to Corcept Therapeutics' net margin of 6.14%. Royalty Pharma's return on equity of 29.25% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Corcept Therapeutics	6.14%	7.40%	5.76%

Royalty Pharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.40	$770.95M	$1.47	37.65
Corcept Therapeutics	$761.41M	11.26	$99.65M	$0.35	228.14

Summary

Royalty Pharma beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Jazz Pharmaceuticals currently has a consensus target price of $246.06, indicating a potential upside of 6.87%. Corcept Therapeutics has a consensus target price of $88.83, indicating a potential upside of 11.25%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.79
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Corcept Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.39	-$356.15M	-$0.02	N/A
Corcept Therapeutics	$761.41M	11.26	$99.65M	$0.35	228.14

In the previous week, Jazz Pharmaceuticals had 1 more articles in the media than Corcept Therapeutics. MarketBeat recorded 15 mentions for Jazz Pharmaceuticals and 14 mentions for Corcept Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.48 beat Corcept Therapeutics' score of 0.39 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Corcept Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics has a net margin of 6.14% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Corcept Therapeutics	6.14%	7.40%	5.76%

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Corcept Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Corcept Therapeutics had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 14 mentions for Corcept Therapeutics and 3 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.39 beat Supernus Pharmaceuticals' score of 0.28 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics presently has a consensus price target of $88.83, indicating a potential upside of 11.25%. Supernus Pharmaceuticals has a consensus price target of $62.17, indicating a potential upside of 39.76%. Given Supernus Pharmaceuticals' higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	11.26	$99.65M	$0.35	228.14
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CORT vs. The Competition

Export

Metric	Corcept Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.56B	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	228.15	18.43	24.92	23.98
Price / Sales	11.26	336.82	529.01	109.54
Price / Cash	88.30	56.31	44.82	54.51
Price / Book	12.96	4.11	10.79	6.50
Net Income	$99.65M	$64.45M	$3.56B	$336.88M
7 Day Performance	-4.61%	2.24%	1.67%	-0.22%
1 Month Performance	32.60%	1.04%	0.43%	0.77%
1 Year Performance	7.50%	30.05%	32.84%	31.57%

Corcept Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CORT Corcept Therapeutics	3.7639 of 5 stars	$79.85 +0.2%	$88.83 +11.3%	+11.7%	$8.56B	$761.41M	228.15	300
ANVS Annovis Bio	2.4231 of 5 stars	$1.75 -2.5%	$13.50 +673.2%	-33.3%	$62.02M	N/A	N/A	3
ZTS Zoetis	4.9617 of 5 stars	$77.26 -2.6%	$133.92 +73.3%	-51.7%	$33.26B	$9.47B	12.81	14,500	Trending News
RPRX Royalty Pharma	4.496 of 5 stars	$53.70 -0.9%	$53.71 +0.0%	+53.7%	$31.22B	$2.38B	36.53	80	Positive News
JAZZ Jazz Pharmaceuticals	3.3549 of 5 stars	$226.93 +0.0%	$246.06 +8.4%	+110.1%	$14.25B	$4.27B	N/A	2,890

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CORT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, ZTS, RPRX, JAZZ, and SUPN

How does Corcept Therapeutics compare to Annovis Bio?

Summary

How does Corcept Therapeutics compare to Zoetis?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, ZTS, RPRX, JAZZ, and SUPN

How does Corcept Therapeutics compare to Annovis Bio?

Which has more risk & volatility, CORT or ANVS?

Is CORT or ANVS more profitable?

Do institutionals & insiders hold more shares of CORT or ANVS?

Does the media refer more to CORT or ANVS?

Which has stronger valuation & earnings, CORT or ANVS?

Do analysts rate CORT or ANVS?

Summary

How does Corcept Therapeutics compare to Zoetis?

Do insiders and institutionals hold more shares of ZTS or CORT?

Which has more volatility and risk, ZTS or CORT?

Do analysts recommend ZTS or CORT?

Is ZTS or CORT more profitable?

Does the media prefer ZTS or CORT?

Which has higher valuation and earnings, ZTS or CORT?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Do institutionals and insiders have more ownership in RPRX or CORT?

Do analysts prefer RPRX or CORT?

Does the media favor RPRX or CORT?

Is RPRX or CORT more profitable?

Which has more volatility and risk, RPRX or CORT?

Which has better valuation & earnings, RPRX or CORT?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Do analysts rate JAZZ or CORT?

Do institutionals & insiders believe in JAZZ or CORT?

Which has more risk & volatility, JAZZ or CORT?

Which has stronger earnings and valuation, JAZZ or CORT?

Does the media prefer JAZZ or CORT?

Is JAZZ or CORT more profitable?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Which has more risk & volatility, CORT or SUPN?

Do insiders & institutionals believe in CORT or SUPN?

Does the media refer more to CORT or SUPN?

Do analysts recommend CORT or SUPN?

Is CORT or SUPN more profitable?

Which has better earnings & valuation, CORT or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools